AWP
REGN icon

Abacus Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Abacus Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$427K Sell
685
-523
-43% -$356K 0.04% 178
2026
Q1 		$933K Buy
1,208
+68
+6% +$52.1K 0.09% 105
2025
Q4 		$880K Buy
+1,140
New +$774K 0.09% 115

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Abacus Wealth Partners's REGN Position: Q2 2026 in Review

Abacus Wealth Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 43% in Q2 2026, selling an estimated $356K and leaving 685 shares worth $427K. The position accounts for 0.04% of the portfolio, ranked #178.

Abacus Wealth Partners first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $933K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Abacus Wealth Partners held 685 shares of Regeneron Pharmaceuticals worth $427K as of Q2 2026.
  • Abacus Wealth Partners sold 523 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $356K.
  • Regeneron Pharmaceuticals made up 0.04% of Abacus Wealth Partners's portfolio in Q2 2026, its #178 holding.
  • Abacus Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Abacus Wealth Partners's Regeneron Pharmaceuticals position peaked at $933K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Abacus Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.